Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXPLAIN-AD canakinumab platform trial in early Alzheimer's disease
2020-003966-38Phase 2Terminated
- Sponsor
- Novartis
- Start
- Apr 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial in Alzheimer's disease (AD) and mild cognitive impairment due to Alzheimer's disease comparing Canakinumab with Placebo (2 arms). Primary endpoint: The Neuropsychological Test Battery (NTB) score. Started Apr 2021; status: terminated.
02
Drugs
canakinumab
03
Conditions
Alzheimer's disease (AD)mild cognitive impairment due to Alzheimer's disease
Beyond the preview
Go deeper on 2020-003966-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003966-38.